1 min read

ACESO Therapeutics announces progress in advancing its cystic fibrosis therapeutic pipeline

ACESO continues to build a scientific foundation for a new generation of cystic fibrosis therapy focused on patients underserved by current treatment options. ACESO Therapeutics is advancing a therapeutic strategy

ACESO continues to build a scientific foundation for a new generation of cystic fibrosis therapy focused on patients underserved by current treatment options.

ACESO Therapeutics is advancing a therapeutic strategy designed to address meaningful gaps in cystic fibrosis care. While current modulators have changed the treatment landscape for many patients, significant unmet needs remain for those who are underserved by existing approaches.

A research-led approach to cystic fibrosis innovation

“To bring transformative therapy to every cystic fibrosis patient, we need innovation that reaches beyond the limits of current treatment options.”

Building for patients without options

ACESO’s pipeline is focused on patients who may not benefit adequately from currently available therapies. By targeting areas of continued unmet need, the company aims to support a broader and more inclusive future for cystic fibrosis treatment.

Next steps

As the company continues to advance its platform, ACESO will share selected updates related to research milestones, pipeline progress, scientific presentations, and partnership development.

Category

Published

January 31, 2026

Reading time

1 min read

Topic

Cystic fibrosis, pipeline development

Recognition

Publication

Press Release

Keep reading

Related news & insights

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for

European Young Investigators Meeting (EYIM) – March 2026

European Young Investigators Meeting (EYIM) - 2026

Get in touch

Partner with us to redefine cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Email

Headquarters

Montpellier, France